Correlation between structural heart disease and cardiac SARS-CoV-2 manifestations

Felix Nägele, Michael Graber, Jakob Hirsch, Leo Pölzl, Sabina Sahanic, Manuel Fiegl, Dominik Hau, Clemens Engler, Sophia Lechner, Anna Katharina Stalder, Kirsten D Mertz, Jasmin D Haslbauer, Alexandar Tzankov, Michael Grimm, Ivan Tancevski, Johannes Holfeld, Can Gollmann-Tepeköylü, Felix Nägele, Michael Graber, Jakob Hirsch, Leo Pölzl, Sabina Sahanic, Manuel Fiegl, Dominik Hau, Clemens Engler, Sophia Lechner, Anna Katharina Stalder, Kirsten D Mertz, Jasmin D Haslbauer, Alexandar Tzankov, Michael Grimm, Ivan Tancevski, Johannes Holfeld, Can Gollmann-Tepeköylü

Abstract

Background: The prognosis of COVID-19 patients with cardiac involvement is unfavorable and it remains unknown which patients are at risk. The virus enters cells via its receptor angiotensin-converting enzyme 2 (ACE2). Myocardial ACE2 expression is increased in structural heart disease (SHD). We, therefore, aimed to analyze correlations between structural heart disease and cardiac SARS-CoV-2 manifestation.

Methods: The clinical course of COVID-19 in patients with structural heart disease was assessed in a prospective cohort of 152 patients. The primary endpoints consisted of hospitalization and survival. Cardiac tissue of 23 autopsy cases with lethal COVID-19 course was obtained and analyzed for (a) the presence of SHD, (b) myocardial presence of SARS-CoV-2 via RT,-PCR, and (c) levels of ACE2 expression using immunofluorescence staining.

Results: Structural heart disease is found in 67 patients, of whom 56 (83.60%) are hospitalized. The myocardium is positive for SARS-CoV-2 in 15 patients (65%) in 23 autopsy cases of lethal COVID-19. Moreover, most hearts with evidence of myocardial SARS-CoV-2 have structural heart disease [11 (91,67%) vs. 1 (8,33%), p = 0.029]. Myocardial presence of SARS-CoV-2 is correlated with a significant downregulation of ACE2 compared to negative control hearts (6.545 ± 1.1818 A.U. vs. 7.764 ± 2.411 A.U., p = 0.003). The clinical course of patients with cardiac SARS-CoV-2 manifestation is unfavorable, resulting in impaired survival (median, 12 days and 4.5 days, respectively, HR 0.30, 95% CI, 0.13 to 0.73, p = 0.0005) CONCLUSIONS: We provide evidence for a correlation between SHD, altered ACE2 receptor expression, and cardiac SARS-CoV-2 manifestation. Consequently, structural heart disease may be considered a distinct risk factor for a severe clinical course after infection with SARS-CoV-2.

Registration number local irb: Ethics Committee of Northwestern and Central Switzerland ID 2020-00629; Ethics Committee of the Medical University Innsbruck EK Nr: 1103/2020.

Gov number: NCT04416100.

Conflict of interest statement

The authors declare no competing interests.

© 2022. The Author(s).

Figures

Fig. 1. Relationship between structural heart disease…
Fig. 1. Relationship between structural heart disease and hospitalization rates upon SARS-CoV-2 infection.
A significant relationship between pathological echo findings and hospitalization rate in 152 patients who tested positive for SARS-CoV-2 could be found (p < 0.0002, Chi-square test).
Fig. 2. Histopathological signs of cardiac hypertrophy…
Fig. 2. Histopathological signs of cardiac hypertrophy in correlation to SARS-CoV-2 infections.
A Patients suffering from structural heart disease showed higher rates of cardiac SARS-CoV-2 infections. (p = 0.0289, Chi-square test). B Representative histopathological images of Hematoxylin/Eosin stained tissue sections from hypertrophic and non-hypertrophic hearts.
Fig. 3. Altered ACE2 expression upon cardiac…
Fig. 3. Altered ACE2 expression upon cardiac SARS-CoV-2 infection.
A Cardiac ACE2 staining intensity was significantly downregulated in hearts with cardiac SARS-CoV-2 viral load (p = 0.003, Unpaired t-test, n = 5 high-power fields per section). B Representative immunofluorescence images of ACE2 and alpha-actinin stained tissue sections from hearts without and with cardiac SARS-CoV-2 infections.
Fig. 4. Cardiac ACE2 and cytokine expression…
Fig. 4. Cardiac ACE2 and cytokine expression levels correlate with cardiac viral load.
A Increased SARS-CoV-2 spike protein RNA expression is significantly correlated with reduced gene expression levels of ACE2 and increased cytokine expression levels of B TNFa, C IL6, and D IFNa (Spearman’s rank correlation, regression slopes are represented by black lines, grey area represents 95% CI, n = 9).
Fig. 5. Short-term survival of 23 COVID-19…
Fig. 5. Short-term survival of 23 COVID-19 fatalities.
Cardiac SARS-CoV-2 infection (blue line, n = 12) correlated with significantly shorter survival (Log-Rank-Test p = 0.005) compared to patients without cardiac viral load (green line, n = 10).

References

    1. Camerer CF, et al. Evaluating the replicability of social science experiments in Nature and Science between 2010 and 2015. Nat. Hum. Behav. 2018;2:637–644. doi: 10.1038/s41562-018-0399-z.
    1. Driggin E, et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J. Am. Coll. Cardiol. 2020;75:2352–2371. doi: 10.1016/j.jacc.2020.03.031.
    1. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat. Rev. Cardiol. 2020;17:259–260. doi: 10.1038/s41569-020-0360-5.
    1. Thum T. SARS-CoV-2 receptor ACE2 expression in the human heart: Cause of a post-pandemic wave of heart failure? Eur. Heart. J. 2020;41:1807–1809. doi: 10.1093/eurheartj/ehaa410.
    1. Nicin L, et al. Cell type-specific expression of the putative SARS-CoV-2 receptor ACE2 in human hearts. Eur. Heart J. 2020;41:1804–1806. doi: 10.1093/eurheartj/ehaa311.
    1. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: Molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46:586–590. doi: 10.1007/s00134-020-05985-9.
    1. Nishiga M, Wang DW, Han Y, Lewis DB, Wu JC. COVID-19 and cardiovascular disease: From basic mechanisms to clinical perspectives. Nat. Rev. Cardiol. 2020;17:543–558. doi: 10.1038/s41569-020-0413-9.
    1. Menter T, Cueni N, Gebhard EC, Tzankov A. Case report: Co-occurrence of myocarditis and thrombotic microangiopathy limited to the heart in a COVID-19 patient. Front. Cardiovasc. Med. 2021;8:809. doi: 10.3389/fcvm.2021.695010.
    1. Amendola, A. et al. Human cardiosphere-derived stromal cells exposed to SARS-CoV-2 evolve into hyper-inflammatory/pro-fibrotic phenotype and produce infective viral particles depending on the levels of ACE2 receptor expression. (2021).
    1. Guzik TJ, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc. Res. 2020;116:1666–1687. doi: 10.1093/cvr/cvaa106.
    1. Sahanic, S. et al. The role of innate immunity and bioactive lipid mediators in COVID-19 and influenza. Front. Physiol. 12, 688946 (2021).
    1. Sonnweber, T. et al. Cardiopulmonary recovery after COVID-19: An observational prospective multicentre trial. Eur. Respir. J.57, 2003481 (2021).
    1. Galderisi M, et al. Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: An expert consensus document of the European Association of Cardiovascular Imag. Eur. Heart J. Cardiovasc. Imaging. 2017;18:1301–1310. doi: 10.1093/ehjci/jex244.
    1. Haslbauer JD, et al. Characterisation of cardiac pathology in 23 autopsies of lethal COVID-19. J. Pathol. Clin. Res. 2021;7:326–337. doi: 10.1002/cjp2.212.
    1. Khokhar SK, Mitui M, Leos NK, Rogers BB, Park JY. Evaluation of Maxwell® 16 for automated DNA extraction from whole blood and formalin-fixed paraffin embedded (FFPE) tissue. Clin. Chem. Lab. Med. 2012;50:267–272. doi: 10.1515/cclm.2011.763.
    1. Gilda JE, et al. A semiautomated measurement of muscle fiber size using the Imaris software. Am. J. Physiol. Physiol. 2021;321:C615–C631. doi: 10.1152/ajpcell.00206.2021.
    1. Huang C, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5.
    1. Hu, B., Guo, H., Zhou, P. & Shi, Z.-L. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol.19, 141–154 (2021).
    1. Shi S, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5:802–810. doi: 10.1001/jamacardio.2020.0950.
    1. Wang Q, et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell. 2020;181:894–904.e9. doi: 10.1016/j.cell.2020.03.045.
    1. Crackower MA, Sarao R, Oliveira-dos-Santos AJ, Da Costa J, Zhang L. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002;417:822–828. doi: 10.1038/nature00786.
    1. Clerkin KJ, et al. COVID-19 and cardiovascular disease. Circulation. 2020;141:1648–1655. doi: 10.1161/CIRCULATIONAHA.120.046941.
    1. Chung CJ, et al. Restructuring structural heart disease practice during the COVID-19 pandemic: JACC review topic of the week. J. Am. Coll. Cardiol. 2020;75:2974–2983. doi: 10.1016/j.jacc.2020.04.009.
    1. Chung MK, et al. SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy. EBioMedicine. 2020;58:102907. doi: 10.1016/j.ebiom.2020.102907.
    1. Fernández-Ruiz I. RAAS inhibitors do not increase the risk of COVID-19. Nat. Rev. Cardiol. 2020;17:383. doi: 10.1038/s41569-020-0401-0.
    1. Glasbey JC, et al. Preoperative nasopharyngeal swab testing and postoperative pulmonary complications in patients undergoing elective surgery during the SARS-CoV-2 pandemic. Br. J. Surg. 2021;108:88–96. doi: 10.1093/bjs/znaa051.
    1. Oudit GY, et al. Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice. Cardiovasc. Res. 2007;75:29–39. doi: 10.1016/j.cardiores.2007.04.007.
    1. Imai Y, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436:112–116. doi: 10.1038/nature03712.
    1. Topol EJ. COVID-19 can affect the heart. Science. 2020;370:408–409. doi: 10.1126/science.abe2813.
    1. Li W, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450–454. doi: 10.1038/nature02145.

Source: PubMed

3
Subscribe